TransCode Therapeutics, Inc.
RNAZ
$6.73
-$0.27-3.86%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -34.66M | -27.13M | -24.60M | -25.51M | -16.76M |
| Total Depreciation and Amortization | 114.20K | 192.30K | 315.00K | 444.40K | 534.80K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 15.02M | 11.80M | 11.59M | 12.45M | 3.24M |
| Change in Net Operating Assets | 15.60K | 617.30K | -1.66M | 128.60K | -351.50K |
| Cash from Operations | -19.52M | -14.52M | -14.35M | -12.50M | -13.34M |
| Capital Expenditure | -6.70K | -500.00 | -13.40K | -18.00K | -21.80K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 2.20K | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -4.40K | -500.00 | -13.40K | -18.00K | -21.80K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 8.85M | 15.94M | 18.38M | 19.17M | 16.40M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | 22.67M | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | -455.70K | -- | -- | -- |
| Cash from Financing | 31.52M | 15.48M | 18.38M | 19.17M | 16.40M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 12.00M | 960.10K | 4.02M | 6.66M | 3.04M |